UBI Pharma's proprietary product, Voriconazole Injection, has received approval for Abbreviated New Drug Application (ANDA) from the United States.

UBI Pharma's developed drug, Voriconazole for Injection, 200 mg/vial (Single-Dose Vial), has been approved by the United States FDA and obtained its Abbreviated New Drug Application (ANDA) certification. The approval letter was received on March 10, 112, Taiwan time.

This product is widely used in the treatment of fungal infections, including invasive aspergillosis, deep-seated candidiasis, esophageal candidiasis, etc. Due to its broad application and clear efficacy, it has been included in the WHO Model List of Essential Medicines (22nd list, 2021). According to IQVIA database, global sales of Voriconazole Injection reached $360 million annually.